Table 4.

Interval specific cumulative incidence rates of select late effects among one-year condition-free survivors post-HCT for acquired SAA between 1995 and 2006 reported to the CIBMTR according to donor type

		Related Donor		Unrelated Donor
	N at Risk	% (95% Confidence Interval)	N at Risk	% (95% Confidence Interval)
Late Effect
Stroke / Seizures
Over next 2 years	707	1.7 (0.9–2.7)	283	1.3 (0.3–2.8)
Over next 5 years	416	1.8 (1.0–2.9)	118	2.8 (1.2–5.1)
Myocardial Infarction
Over next 2 years	736	0	293	0
Over next 5 years	435	0.1 (0.0–0.5)	127	0
Cirrhosis
Over next 2 years	737	0	290	0.3 (0.0–1.2)
Over next 5 years	436	0	127	0.3 (0.0–1.2)
Gonadal dysfunction / Infertility
Over next 2 years	709	2.6 (1.6–3.8)	273	6.2 (3.8–9.1)
Over next 5 years	419	3.0 (2.0–4.3)	108	10.5 (7.3–14.3)
Renal Failure
Over next 2 years	715	1.1 (0.5–1.9)	287	1.9 (0.7–3.6)
Over next 5 years	425	1.4 (0.7–2.3)	127	2.4 (0.9–4.5)
Avascular necrosis
Over next 2 years	724	1.4 (0.7–2.3)	276	3.2 (1.5–5.4)
Over next 5 years	426	1.8 (1.0–2.8)	117	6.3 (3.6–9.7)
Cataracts
Over next 2 years	734	0.6 (0.2–1.2)	284	2.2 (0.9–4.1)
Over next 5 years	433	1.1 (0.5–1.9)	118	5.1 (2.9–8.0)
Growth disturbance
Over next 2 years	735	0.2 (0.0–0.7)	286	1.9 (0.7–3.6)
Over next 5 years	433	0.5 (0.1–1.2)	113	7.2 (4.4–10.7)
Hypothyroidism
Over next 2 years	731	0.7 (0.3–1.4)	286	0.6 (0.1–1.8)
Over next 5 years	432	1.2 (0.5–2.1)	119	5.5 (2.8–9.0)
Solid tumors
Over next 2 years	852	0.2 (0.0–0.6)	291	0.6 (0.1–1.8)
Over next 5 years	549	0.3 (0.1–0.8)	126	1.6 (0.5–3.3)
Lymphoma
Over next 2 years	851	0.1 (0.0–0.4)	280	0.6 (0.1–1.8)
Over next 5 years	550	0.1 (0.0–0.4)	124	0.6 (0.1–1.8)